Biomarker and Antibody Development for Asthma

Creative Biolabs is a well-recognized expert in the field of antibody generation and production. Especially, we have launched a series of in vitro diagnostic (IVD) antibody development services for different infections and diseases. Here, we introduce our antibody development services targeting different biomarkers of asthma.

Introduction to Asthma

Biomarker and Antibody Development for Asthma Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurrent symptoms, reversible airflow obstruction and bronchospasm. Asthma has been confirmed as early as ancient Egypt. It usually starts in childhood. Since the 1960s, the incidence of asthma has increased significantly. Common signs and symptoms of asthma include wheezing, coughing, chest tightness, shortness of breath, etc. Symptoms can be prevented by avoiding triggering factors (such as allergens and irritants) and using inhaled corticosteroids. If asthma symptoms are not controlled, long-acting beta-agonists (LABA) or anti-leukotriene drugs may be used in addition to inhaled corticosteroids. Treatments for rapidly worsening symptoms are usually an inhaled short-acting beta-2 agonists such as salbutamol and oral corticosteroids. In severe cases, intravenous injections of corticosteroids, magnesium sulfate, and hospitalization may be required.

Diagnostic Tools of Asthma

Making improvements in diagnosis and monitoring of asthma is important to identify susceptible individuals and to start early treatment. Traditional diagnostic techniques mainly rely on clinical features (symptoms), spirometry examinations, or peak flow rate measurements. However, the clinical features of asthma are non-specific and pulmonary function tests are often insensitive. Non-invasive biomarkers that can be measured in easily obtainable samples, such as the exhaled gases, sputum, blood, and urine, have been discovered and validated to be useful in clinical practice. Moreover, novel biomarkers that may be associated with asthma are continuously emerging. The combination of these diagnostic tools improves diagnostic accuracy and management of asthma.

IVD Antibody & Immunoassay Development Services Provided by Creative Biolabs

Non-invasive IVD tests that apply the immunoassay technology have been developed targeting some of the asthma biomarkers. They measure single analyte or multiple analytes in blood, urine, or other samples, to aid in screening and diagnosis, severity assessment, therapy guiding, disease control, and prognosis of asthma. As more and more technology platforms and new biomarkers are emerging, new diagnostic kits are being developed as well, to provide a quicker, more specific and more accurate diagnosis of asthma. Most of these IVD immunoassays are based on the use of antibodies/antigens to detect the analytes.

The development of diagnostic immunoassays is a time-consuming, resource-intensive effort. Particularly, the use of high-quality reagents, antibodies or antigens, is of great importance to achieve higher sensitivity and accuracy. Creative Biolabs has built a versatile IVD antibody development platform to provide custom IVD antibody development services for a broad range of disease biomarkers. Besides, we also help our clients with contract research in immunoassay development, providing support in assay design, critical raw material sourcing, component formulation, assay optimization & validation, and kit production. Our expertise lies in a broad array of immunoassay platforms, including ELISA (enzyme-linked immune-sorbent assay), LFIA (lateral flow immunoassay), CLIA (chemiluminescent immunoassay), IHC (immunohistochemistry), etc. For asthma, we focus on various biomarkers including but not limited to:

EDN ECP Periostin Others

Features of Our Services

  • Our repertoire includes both established and novel biomarkers
  • A specialized technical team and abundant experience in antibody/immunoassay development
  • State-of-the-art techniques and short turnaround time
  • Services are tailored to meet the needs of our valued IVD clients

Please feel free to contact us to discuss your project requirements.

References

  1. Wan, X. C., (2016). "Biomarkers in severe asthma." Immunology and Allergy Clinics, 36(3), 547-557.
  2. Fatemi, F., (2014). "Biomolecular markers in assessment and treatment of asthma." Respirology, 19(4), 514-523.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Follow us on:
Copyright ©2011 - 2020 Creative Biolabs.